Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium.

J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.


Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.


A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.


Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH.

Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.


Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.


Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62. Epub 2005 Sep 1.


Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.


Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.

Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, Barnes GL, Hoffman J, Chaisson RE, McIlleron H, Dorman SE.

Int J Tuberc Lung Dis. 2015 Jul;19(7):780-6. doi: 10.5588/ijtld.14.0868.


Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.

Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2004 Jun 1;169(11):1191-7. Epub 2004 Feb 12.


Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.

Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA.

Int J Tuberc Lung Dis. 2002 Jan;6(1):3-10.


Rifapentine for the treatment of pulmonary tuberculosis.

Munsiff SS, Kambili C, Ahuja SD.

Clin Infect Dis. 2006 Dec 1;43(11):1468-75. Epub 2006 Oct 24. Review.


Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.


Rifapentine: its role in the treatment of tuberculosis.

Temple ME, Nahata MC.

Ann Pharmacother. 1999 Nov;33(11):1203-10. Review.


Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL.

PLoS Med. 2007 Dec;4(12):e344.


Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.


Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S; Tuberculosis Trials Consortium.

Lancet. 2002 Aug 17;360(9332):528-34.


High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team.

N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.


Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.

Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6. Epub 2006 Feb 10.


Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.

Zvada SP, Denti P, Geldenhuys H, Meredith S, van As D, Hatherill M, Hanekom W, Wiesner L, Simonsson US, Jindani A, Harrison T, McIlleron HM.

Antimicrob Agents Chemother. 2012 Aug;56(8):4471-3. doi: 10.1128/AAC.00404-12. Epub 2012 May 14.

Supplemental Content

Support Center